Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya Majalah Kedokteran Sriwijaya Bioscientia Medicina : Journal of Biomedicine and Translational Research Bioscientia Medicina : Journal of Biomedicine and Translational Research
Rini Nindela
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Karakteristik Penderita Kejang Demam di Instalasi Rawat Inap Bagian Anak Rumah Sakit Muhammad Hoesin Palembang Rini Nindela; Msy. Rita Dewi; Iskandar Z Ansori
JURNAL KEDOKTERAN DAN KESEHATAN Vol 1, No 1 (2014)
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Kejang demam adalah bangkitan kejang yang terjadi pada kenaikan suhu tubuh (suhu rektal di atas 38oC) yang disebabkan oleh proses ekstrakranial. Beberapa faktor demografi seperti usia dan jenis kelamin turut membentuk pola terjadinya kejang demam. Manifestasi klinis dan pungsi lumbal sangat penting dalam mengklasifikasikan dan membantu menegakkan diagnosis kejang demam. Hingga kini angka kejadian kejang demam masih cukup tinggi tapi belum ada data mengenai karakteristik kejang demam secara keseluruhan. Penelitian ini bertujuan untuk mengetahui distribusi penderita kejang demam berdasarkan karakteristik demografi dan klinis. Populasi penelitian adalah penderita kejang demam yang dirawat inap di RSMH Palembang sejak Januari 2006 hingga Januari 2008. Dari data yang terdapat dalam rekam medik diketahui bahwa angka kejadian kejang demam selama periode tersebut sebesar 37,2%. Kejang demam paling banyak menyerang anak laki-laki dengan usia 1-2 tahun. Pencetus kejang demam yang utama adalah infeksi saluran napas atas. Kejang paling sering terjadi selama ≤ 15 menit, dengan frekuensi ≥ 2 kali kejang dalam 1 periode demam, bersifat umum dengan jenis tonik klonik. Sebagian besar kejang yang dialami penderita tergolong dalam KDK. Lebih dari separuh total sampel memiliki faktor risiko kejang demam berulang dan epilepsi. Hanya sebagian kecil penderita menjalani pemeriksaan pungsi lumbal, EEG dan CT-scan. Kebanyakan penderita mendapat profilaksis intermitten.
Merozoite Surface Protein-1 (MSP-1) dan Merozoite Surface Protein-2 (MSP-2) Plasmodium falciparum sebagai Kandidat Vaksin Malaria Rini Nindela
Majalah Kedokteran Sriwijaya Vol 47, No 1 (2015): Majalah Kedokteran Sriwijaya
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36706/mks.v47i1.2745

Abstract

Plasmodium falciparum—parasit malaria—menginfeksi miliaran dan membunuh jutaan orang setiap tahun. Rangkaian  usaha pengendalian malaria; kelambu berinsektisida, indoor residual spraying, dan kemoterapi dibayangi oleh ancaman resistensi. Karenanya, vaksin malaria yang efektif sangat dibutuhkan. Pengembangan vaksin dihambat oleh kompleksitas parasit dengan ribuan antigen berbeda yang diekspresikan di masing-masing tahap dalam siklus hidupnya. Bagaimanapun, penelitian selama beberapa dekade tidaklah sia-sia. RTS,S, vaksin stadium pre-eritrositik, mungkin akan menjadi vaksin pertama yang mendapat lisensi, terlepas dari efikasinya yang hanya sekitar 30-50% . Antigen-antigen pada stadium lainnya juga diteliti sebagai kandidat vaksin, termasuk Merozoite Surface Protein/MSP-1 dan MSP-2, yang terbukti menginduksi respon imun yang protektif terhadap malaria, baik secara alamiah maupun eksperimental. Namun, keragaman genetik menjadi penghalang dalam pengembangan vaksin berbasis kedua antigen ini. Pemahaman yang menyeluruh tentang struktur MSP-1 dan MSP-2 P. falciparum serta mekanisme imun hospes terhadap keduanya akan memandu kepada tersedianya vaksin MSP-1 dan MSP-2 dengan efikasi yang optimal.
Vitamin D Levels in Epilepsy Patients at the Neurology Polyclinic, Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia Sri Handayani; Partan, Radiyati Umi; Zen Hafy; Fitri Octaviana; Citra Ananta Avis; Rini Nindela; Selly Marisdina
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 12 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i12.949

Abstract

Background: In epilepsy patients, treatment is often lifelong and anti-epileptic drugs (AEDs) can be divided into two general groups, namely drugs that affect cytochrome P-450 (CYP-450) such as carbamazepine, phenytoin, primidone, or valproic acid, and those that affect minimal cytochrome P-450 such as gabapentin, vigabatrin, levetiracetam, oxcarbazepine, or topiramate. AEDs include various drugs that can cause a decrease in vitamin D levels. Therefore, this study was aimed at examining vitamin D levels in epilepsy patients who took AEDs at the neurology polyclinic at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Methods: This research is a descriptive study with a cross-sectional design using primary data obtained from the results of patient examinations using laboratory tests and secondary data from medical records. Results: As many as 78% (14 subjects) who received monotherapy had vitamin D levels below normal, and 16 subjects, or 76%, who received polytherapy had vitamin D levels below normal (p = 0.907). A total of 13 (72%) subjects who received phenytoin had vitamin D levels below normal, as well as 5 (63%) subjects who received carbamazepine and 12 (92%) subjects who received other therapies (p = 0.235). A total of 12 (67%) subjects who received therapy for 1-3 years and 18 (86%) subjects who received therapy > 3 years had vitamin D levels below normal (p = 0,406). Conclusion: Vitamin D deficiency is a crucial problem in epilepsy patients receiving AED therapy, where more than 75% of patients have vitamin D deficiency. In this study, vitamin D deficiency did not have a significant relationship with the type of therapy (monotherapy or polytherapy) or the type of drug used. used, duration of therapy, and frequency of sun exposure.
Vitamin D Levels in Epilepsy Patients at the Neurology Polyclinic, Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia Sri Handayani; Partan, Radiyati Umi; Zen Hafy; Fitri Octaviana; Citra Ananta Avis; Rini Nindela; Selly Marisdina
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 12 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i12.949

Abstract

Background: In epilepsy patients, treatment is often lifelong and anti-epileptic drugs (AEDs) can be divided into two general groups, namely drugs that affect cytochrome P-450 (CYP-450) such as carbamazepine, phenytoin, primidone, or valproic acid, and those that affect minimal cytochrome P-450 such as gabapentin, vigabatrin, levetiracetam, oxcarbazepine, or topiramate. AEDs include various drugs that can cause a decrease in vitamin D levels. Therefore, this study was aimed at examining vitamin D levels in epilepsy patients who took AEDs at the neurology polyclinic at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Methods: This research is a descriptive study with a cross-sectional design using primary data obtained from the results of patient examinations using laboratory tests and secondary data from medical records. Results: As many as 78% (14 subjects) who received monotherapy had vitamin D levels below normal, and 16 subjects, or 76%, who received polytherapy had vitamin D levels below normal (p = 0.907). A total of 13 (72%) subjects who received phenytoin had vitamin D levels below normal, as well as 5 (63%) subjects who received carbamazepine and 12 (92%) subjects who received other therapies (p = 0.235). A total of 12 (67%) subjects who received therapy for 1-3 years and 18 (86%) subjects who received therapy > 3 years had vitamin D levels below normal (p = 0,406). Conclusion: Vitamin D deficiency is a crucial problem in epilepsy patients receiving AED therapy, where more than 75% of patients have vitamin D deficiency. In this study, vitamin D deficiency did not have a significant relationship with the type of therapy (monotherapy or polytherapy) or the type of drug used. used, duration of therapy, and frequency of sun exposure.
Co-Authors Citra Ananta Avis Fitri Octaviana Iskandar Z Ansori Msy. Rita Dewi Radiyati Umi Partan, Radiyati Umi selly marisdina Sri Handayani Zen Hafy